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SUmmARy – Radiotherapy presents one of the essential modes of treatment in patients with 
prostate cancer at almost any stage of the disease. it can be delivered as external beam radiotherapy, as 
brachytherapy or two methods combined. higher radiation doses are proven to be more effective than 
low doses and moderate hypofractionation with doses up to 3.4 Gy per fraction is proven equivalent 
to standard fractionation using 1.8- 2 Gy per fraction. Stereotactic body radiotherapy (SBRt) with 
doses from 3.4 to 7.25 Gy per fraction presents valuable option in certain subgroups of patients. in 
case of local regional disease relapse, radiotherapy is used in curative setting.
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Introduction
Radiotherapy in prostate cancer is undoubtedly ef-
ficacious treatment. in last decades a number of clini-
cal trials exploring different radiotherapy modalities 
and schedules regarding dose and fractionation have 
been published. nevertheless, due to methodological 
limits, it can be quite difficult to compare the results of 
various trials. in 1985 prostate specific antigen (PSA) 
was introduced. That has caused a significant down-
ward risk migration over time, which had the impact 
on treatment (1). in 2016 international Society of 
Urological Pathology (iSUP) published consensus on 
contemporary grading and new prostate cancer grad-
ing system was introduced as a validated alternative to 
the Gleason score. That led to further risk group strat-
ification (2, 3). heterogeneity of used endpoints also 
contributes to methodological limits: overall survival, 
cancer specific survival, clinical relapse, biochemical 
relapse, not to mention various definitions of bio-
chemical relapse. All those limits make interpretation 
and comparison of results of reported clinical trials, as 
well as their implementation in the current practice 
quite challenging.
The aim of this article is to present landmark trials 
that led to change of practice regarding the dose of 
radiotherapy, hypofractionation, use of stereotactic ra-
diotherapy, brachytherapy and the role of radiotherapy 
in locoregional disease relapse.
Methods
A literature search of medline via Pubmed was 
performed for the following terms: “Rt”, “radiation”, 
“irradiation”, “prostatic neoplasms/Rt”, “brachythera-




A number of clinical trials have addressed the role 
of dose escalation on the disease outcome and the tox-
icity of higher doses.
one of the first dose escalation trails was medical 
Research Council (mRC) 01 trial. it randomized 843 
patients whose prostate cancer was staged as t1b- t3a 
n0 m0 and PSA level was less than 50 mg/ml, to 
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receive either 64 Gy in 32 fractions, conformal radio-
therapy, which was standard dose at the time (control 
group), or 74 Gy in 37 fractions (dose-escalated 
group). Three to six months before the beginning of 
irradiation, neoadjuvant androgen deprivation therapy 
started, and was continued until the end of radiation 
treatment. After a median follow up of 10 years, bio-
chemical progression-free survival was 43% in the 
control group and 55% in the dose-escalated group (p 
= 0.0003). no difference was observed in overall sur-
vival; it was 71% in each group. Patients allocated to 
dose-escalated group had an increased rate of both 
acute and late toxicity (4).
GetUG06 trial randomized 306 patients with lo-
calized prostate cancer to receive 70 Gy or 80 Gy on 
prostate, without androgen deprivation. After 61 
months of follow up, the 5-year biochemical relapse 
rate was 32% and 23.5%, respectively (p = 0.09) using 
Phoenix definition (nadir PSA plus 2 ng/ml). Better 
biochemical outcome for the higher dose group was 
observed in patients whose initial PSA levels were 
above 15 ng/ml. no difference in mortality between the 
two treatment approaches was noticed. higher dose 
group patients had significantly more grade 2 urinary 
toxicity (17.5% compared to 10% at 70 Gy, p = 0.046) 
and bladder toxicity (p = 0.039). no significant differ-
ences in grade 2 or greater rectal toxicity nor in quality 
of life were reported among the patient groups (5).
in the dutch trial, in 664 patients with t1b-t4n0 
prostate cancer doses of 78 Gy and 68 Gy were com-
pared. Use of androgen deprivation therapy was al-
lowed. Biochemical and/or clinical failure (BCf) was 
trial’s primary endpoint. Both AStRo (American 
Society for Therapeutic Radiology and oncology) 
guidelines (3 consecutive PSA rises) and Phoenix def-
inition (nadir PSA plus 2 ng/ml) were used to define 
it. After 110 months of follow up, BCf and local fail-
ure (lf) rates were significantly lower in the group of 
patients receiving 78 Gy (p < 0.05). however, no dif-
ferences in clinical failure (Cf), death from prostate 
cancer (PCd), and overall survival (oS) were observed 
(6, 7).
in the trial published by Kuban et al., 301 t1b-t3 
prostate cancer patients were randomized to receive 70 
Gy or 78 Gy. median follow up was 9 years. higher 
biochemical and clinical failure rates, as well as higher 
risk of dying of prostate cancer, were observed in pa-
tients with high-risk disease or with pre-treatment 
PSA level > 10 ng/ml, if irradiated to 70 Gy. if treated 
with 70 Gy, patients that were less than 70 years old at 
treatment died three times more frequently of prostate 
cancer than of other causes. in this age group, patients 
were more likely to die from other causes if irradiated 
with 78 Gy. Patients that were 70 or older died of both 
prostate cancer and of other causes equally, if treated 
with 70 Gy. in this age group, not a single patient re-
ceiving 78 Gy died of prostate cancer. in conclusion, in 
patients with high-risk disease moderate dose escala-
tion using radiation dose of 78 Gy offers better bio-
chemical and clinical control and decreases death from 
prostate cancer. That also applies to patients whose 
pre-treatment PSA levels were above 10 ng/ml (8).
total of 1532 prostate cancer patients were en-
rolled in nRG oncology RtoG 0126 Randomized 
Clinical trial. Patients’ characteristics were the follow-
ing: clinical stage t1b to t2b, Gleason score (GS) 2 to 
6 with prostate specific antigen (PSA) values between 
10- 20 ng/ml; or GS 7 with PSA levels less than 15 
ng/ml. Patients were randomized to receive 79.2 Gy in 
44 daily fractions of 1.8 Gy or 70.2 Gy in 39 daily 
fractions of 1.8 Gy. Three-dimensional conformal ra-
diation therapy (3d CRt) or intensity-modulated ra-
diation therapy (imRt) were used as radiation tech-
niques. Study endpoints were overall survival (oS), 
biochemical failure (Bf, Phoenix or AStRo defini-
tion) and frequency of acute and late radiation treat-
ment toxic effects. Acute side effects were those occur-
ring less than 90 days of the start of the treatment. in 
case side effects occurred more than 90 days from the 
start of the treatment, they were defined as late side 
effects.
After a median follow up of 8.4 years, there was no 
difference in oS between the groups; oS rates were 
76% in group of patients receiving 79.2 Gy and 75% in 
the group of patients receiving 70.2 Gy (p = 0.98). dis-
tant metastases occurred in 4% and 6%, respectively 
(p = 0.05). Biochemical failure, as per AStRo defini-
tion, after 5 and 8 years of follow up, occurred in 40% 
and 47% of patients allocated to 70.2-Gy arm. in pa-
tients receiving 79.2 Gy, those figures were 25% and 
31%, respectively (p < 0.001). Salvage therapy, namely 
androgen deprivation, cryosurgery or brachytherapy, 
was significantly more often used in patients in the 
70.2-Gy arm (p < 0.001). frequency of acute gastroin-
testinal (Gi) and genitourinary (GU) toxicity was not 
significantly different between the arms. however, af-
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ter 5 years of follow up, late grade 2 or greater Gi and/
or GU toxicity was significantly more often in 79.2-
Gy group (9).
two meta-analyses tried to determine the differ-
ence in outcomes of patients with localized prostate 
cancer regarding radiotherapy dose; namely is high-
dose radiotherapy (hdRt) more efficient than con-
ventional-dose radiotherapy (CdRt).
meta- analysis by Viani et al. quantified if the total 
radiotherapy dose has an impact on biochemical con-
trol of the disease. it analyzed the data from 2812 pa-
tients enrolled in seven randomized controlled trials. if 
patients were treated with high doses, biochemical 
failure incidences were significantly reduced (p < 
0.0001). That benefit was consistent across the risk 
groups. no difference has been observed between the 
treatment groups regarding mortality rate (p = 0.38) 
and specific prostate cancer mortality rate (p = 0.45). 
late grade >2 gastrointestinal toxicity was more fre-
quent after hdRt. According to the authors, these 
results suggest that hdRt provides a better therapeu-
tic option for patients in all risk groups - low, interme-
diate and high (10).
Zan et al. in their meta-analysis evaluated 6 ran-
domized controlled trials of long-term follow-ups to 
assess efficacy and toxicity of hdRt and CdRt. tri-
als included 2,822 patients. in terms of 10- year effi-
cacy, hdRt was associated with a significant reduc-
tion of biochemical failure rates: 34.0 % vs. 24.7 %, p < 
0.00001, but no difference was observed in overall sur-
vival (73.4 % vs. 74.3 % p = 0.64) and prostate cancer 
specific survival (PCSS; 90.7 % vs. 91.6 %, p = 0.47). 
decrease of biochemical failure at 10 years was consis-
tent in all trials, regardless of androgen deprivation 
therapy. Patients treated with hdRt had a signi-
ficantly later grade 2 or higher (G ≥ 2) Gi (28.0 % 
vs. 18.6 %, p < 0.00001) and GU toxicity (22.6 % vs. 
19.5 %, p = 0.04). There was no significant difference 
in quality of life between hdRt and CdRt (p > 
0.05). Since the advantage in biochemical control did 
not translate into an improvement in oS and PCSS 
and hdRt was connected with worse late toxicity 
outcomes, these authors are more cautious and suggest 
that hdRt should be discreetly used in the treatment 
of patients with prostate cancer (11).
Kalbasi and al. analyzed the data of 42,481 prostate 
cancer patients from national Cancer data Base 
(nCdB). 12 229 patients had a low risk, 16,714 inter-
mediate risk and 13 538 high risk disease. They under-
went radiotherapy in the period between 2004 and 
2006. Threshold for distinction between the groups 
was 75.6 Gy; therefore, doses between 68.4 and 75.6 
Gy were referred as standard dose and those between 
75.6 and 90 Gy as escalated dose.
Patients with intermediate and high-risk prostate 
cancer had a better oS if treated with higher doses (p< 
0.001). however, this benefit has not been shown for 
low risk prostate cancer patients (p = 0.54). in inter-
mediate risk group a 7.8% reduction of death risk has 
been observed with every 2 Gy dose increment. in 
high risk group death risk reduction per every 2 Gy 
dose increment was 6.3% (12).
trials are summarized in table 1. (13)
Hypofractionated radiation  
therapy- hypofractionation
term standard fractionation stands for the delivery 
of radiotherapy in daily doses (fractions) of 1.8 -2 Gy. 
in case daily doses higher than 2 Gy are being used, 
that kind of radiation treatment is referred to as hypo-
fractionated radiation therapy or hypofractionation. 
The α/β ratio is a radiobiological parameter explaining 
how normal and cancer tissues would respond to dif-
ferent radiation schedules. According to literature 
data, α/β ratio of prostate cancer is assumed to be 
about 1.5; therefore, sensitivity of prostate cancer on 
fraction size is to be expected. hypofractionation 
could be moderate with daily fractions between 2.1 
and 3.4 Gy or extreme, in case daily fractions higher 
than 3.4 Gy are used.
Besides expected clinical benefit, hypofractionated 
radiation treatment is given in lower number of radia-
tion sessions. That makes overall treatment time short-
er, which is more convenient for both patient and staff.
Moderate hypofractionation
A number of randomized clinical trials evaluated 
use of moderate hypofractionation (mh) in prostate 
cancer patients. Basically, short biochemical disease 
control between treatment arms was similar. however, 
due to short follow up, long-term effects on organs at 
risk, namely bowel and bladder, are not yet completely 
recognized.
first randomized studies were undertaken in Aus-
tralia and Canada. The rationale of the hypofraction-
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ation, however, was not prostate cancer α/β ratio but 
the convenience of shorter overall treatment time. due 
to countries’ size, in both Australia and Canada pa-
tients had to travel large distances in order to get ra-
diotherapy (14).
in nCi Canada trial with a reported median fol-
low up of 5.7 years, 936 patients were enrolled. Pros-
tate cancer was staged as clinically t1-t2 and PSA 
levels had to be below 40 ng/ml. Patients were ran-
domized to receive hypofractionated radiotherapy 
(52.5 Gy in daily fractions of 2.62 Gy) or convention-
ally fractionated radiotherapy (66 Gy in 33 daily frac-
tions of 2 Gy). no concomitant antiandrogen therapy 
was used. Biochemical or clinical failure (BCf) was set 
Table 1 Dose escalation trials in localized prostate cancer (13)
trial no of patients Stage
Radiation 





843 t1b-t3a n0m0, 
PSA<50 ng/ml
neoadj. ht







BfS 43% 64Gy, 55% 
74Gy (p= 0.0003),
oS 71% both groups 
(p= 0.96)
GetUG 06
Beckendorf et al. 
int J Radiat 
oncol Biol Phys 
2011
306 t1b-3a, n0, m0, 
PSA<50 ng/ml













164 patients with 
neoadjuvant ht








fff 43% 68Gy,  
49% 78 Gy  
(p= 0.045)
md Anderson
Kuban et al. int J 
Radiat oncol 
Biol Phys, 2011
301 t1-3, n0, m0, 
PSA 10 ng/ml vs. 
PSA >10 ng/ml





other cause  
of death
high risk:  
(PSA> 10): dSm 
16% 70Gy, 4% 78Gy 
(p=0.05)
higher risk dSm 
15% 70Gy, 2% 78.
Gy (p=0.03)
RtoG 0126, 




iSUP grade 1 +
PSA 10-20 ng/ml
or
iSUP grade 2/3 +
PSA < 15 ng/ml
70.2 vs.  
79.2 Gy









75% oS at 70.2 Gy
76% oS at 79.2 Gy
6% dm at 70.2 Gy
4% dm at 79.2 Gy
(p = 0.05)
47% BCf at  
70.2 Gy
31% BCf at  
79.2 Gy
(p < 0.001;
Phoenix, p < 0.001)
retrospective 
nCdB trial






low risk, 22% ht
intermediate risk, 
49% ht
high risk,  
77% ht







hR 0.98, for dose 
escalation (p= 0.54)
hR 0.84 for dose 
escalation (p<0.001)
hR 0.82 for dose 
escalation (p< 0.001)
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as the study’s primary outcome. At 5 years, the BCf 
probability in the short arm was 59.95% and in the 
long arm 52.95%. Those data gave the advantage to the 
long arm approach. There was no difference between 
the arms regarding overall survival or 2-year post-ra-
diotherapy biopsy. When compared to the long arm, 
patients in the short arm had a higher frequency of 
acute toxicity (11.4% vs. 7%). no difference was de-
tected between the arms in terms of the late toxicity 
(3.2%). it should be stressed that doses used in both 
arms of the trial are lower than those being used now-
adays (15).
in Australian trial 217 patients were randomized to 
either hypofractionated or conventionally fractionated 
radiation treatment. Patients in hypofractionated arm 
received 55 Gy during 4 weeks in 20 daily fractions 
and patients in the control arm received 64 Gy in 32 
daily fractions; their overall treatment time was 6.5 
weeks. it is to notice that 156 patients received two-
dimensional radiotherapy and for Rt planning two-
dimensional computed tomography method was used. 
After a median follow up of 90 months, biochemical 
relapse, which was defined as nadir PSA +2 ng/ml oc-
curred in 36 patients in the hypofractionated group 
and in 49 patients in the control group. Therefore, 90- 
month biochemical relapse free survival turned out to 
be significantly better with the hypofractionated 
schedule (53% vs. 34%). There was no difference in 
overall survival between the arms. Genitourinary and 
gastrointestinal toxicity was similar between the 
schedules and it persisted 60 months upon radiothera-
py (16).
These first hypofractionation trials undoubtedly 
demonstrated feasibility of the concept, but due to ap-
plied radiotherapy techniques and doses that no longer 
present standard of care, their efficacy and toxicity data 
should be taken into consideration cautiously.
Three modern, large randomized trials evaluated 
non-inferiority of moderate hypofractionation to con-
ventional fractionation: ChhiP, RtoG 0415 and 
PRofit.
Chhip study was a randomized controlled phase 
3 trial that included 33 216 patients with prostate can-
cer, clinically staged as t1b-t3an0m0. Study arms, 
according to radiation schedules, were the following: 
60 Gy given in 20 3- Gy daily fractions, 57 Gy given 
in 19 3- Gy daily fractions and the control arm of 74 
Gy in 37 2-Gy daily fractions. intensity modulated ra-
diotherapy was used. Whole pelvis radiotherapy was 
not given. in 97% of patients both neoadjuvant and 
concomitant antiandrogen therapy was used. image 
guided radiotherapy was not performed in 53% of pa-
tients, equally in each arm of the trial. median follow 
up was 64 months and biochemical or clinical failure 
(BCf) was set up as the study outcome. At five years, 
the proportion of patients that were BCf free was 
90.6% for 60 Gy in 20 fractions, 85.9% for 57 Gy in 19 
fractions and 88.3% for standard fractionation- 74 Gy 
in 37 fractions. Therefore 60 Gy was proven to be non-
inferior to 74 Gy. When compared to the control arm, 
57 Gy could not be claimed non-inferior. late toxicity 
was not significantly different between the treatment 
arms. frequencies of bladder and bowel grade ≥ 2 ad-
verse reactions were 11.7% and 11.9% respectively for 
60 Gy group, 6.6% and 11.3% for 57 Gy group and 
9.1% and 13.7% for the control group (17).
in RtoG 0415 trial 1115 low-risk prostate cancer 
patients were randomized to receive 73.8 Gy given in 
41 daily fractions of 1.8 Gy during 8.2 weeks, which 
was conventional regimen (C-Rt, Cf), or 70 Gy given 
in 28 fractions of 2.5 Gy through 5.6 weeks (hypofrac-
tionated radiotherapy, h-Rt). The trial was designed 
to establish if the 5-year disease-free survival (dfS) of 
patients who underwent hypofractionated radiothera-
py would not be worse than 5-year dfS of conven-
tionally irradiated patients by more than 7.65% (hR < 
1.52). Androgen suppression was not allowed, except 
in case of prostate cancer recurrence as a salvage treat-
ment. median follow up was 5.8 years. The estimated 
5-year (dfS) was 86.3% in the h-Rt arm and 85.3% 
in the C-Rt arm. The dfS hR was 0.85, therefore 
meeting predefined non-inferiority criterion (p < 
0.001). no significant difference in acute toxicities was 
observed between the arms. Patients in h-Rt arm of 
the trial had more often late grade 2 and 3 genitouri-
nary and gastrointestinal adverse events (hR 1.31 to 
1.59) (18).
1206 intermediate-risk prostate cancer patients 
were enrolled in PRofit trial. Patients allocated in 
hypofractionated arm of the trial received 60 Gy in 20 
daily fractions; overall treatment time was 4 weeks. Pa-
tients in the control arm (conventional Rt) received 
78 Gy in 39 daily fractions. Patients were not permit-
ted to receive androgen deprivation treatment. Bio-
chemical-clinical failure (BCf) was set up as the pri-
mary outcome. it included PSA failure (defined as 
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nadir PSA value + 2), hormonal treatment, clinical re-
lapse (local or distant) or prostate cancer death. no 
difference has been observed between the arms in 
5-year BCf after a median follow up of 6 years (85%). 
no significant differences have been reported in over-
all survival or late grade ≥ 3 genitourinary and gastro-
intestinal toxicity (19).
even though these three trials enrolled different 
risk group patients and the use of androgen depriva-
tion therapy among them varied, all of them met their 
primary aim to prove non-inferiority of moderate hy-
pofractionation to conventional fractionation. Regard-
ing late toxicity, no difference between the two arms 
was reported in ChhiP and PRofit trial, while in 
RtoG trial late toxicity was more common with mf.
four superiority randomized trials failed to demon-
strate any difference in efficacy, including metastasis-
free, cancer-specific survival and overall survival (14).
hyPRo trial included 820 patients with localized 
t1b-4 prostate cancer. Their PSA level had to be be-
low 60 ng/ml and they were staged as intermediate or 
high-risk. Patients were randomized to receive either 
hypofractionated or conventionally fractionated radio-
therapy. hypofractionated regimen (hf) consisted of 
64.6 Gy given in 19 fractions, 3.4 Gy each, three times 
a week. Conventional regimen (Cf) was 78 Gy in 39 
daily fractions over 8 weeks. equivalent total dose for 
hypofractionation was 90.4 Gy (calculated using α/β 
ratio of 1.5 Gy for prostate cancer), which was consid-
erably higher than 78 Gy given in the control group in 
conventional manner. Concomitant hormonal therapy 
was given to 67% of patients; its median duration was 
32 months. Relapse-free survival (RfS) was the study’s 
primary endpoint.
After a median follow-up of 60 months, patients 
allocated to hypofractionation arm had a 5-year RfS 
of 80.5% and patients irradiated conventionally had a 
5-year RfS of 77.1%. There was no difference in fre-
quency of G ≥2 gastrointestinal or genitourinary toxic-
ity 3 months upon radiotherapy. however, 120 days 
upon treatment, G ≥2 acute gastrointestinal toxicity 
was more frequent after hypofractionation: 42% vs. 
31.2%. Regarding late toxicity, for grade 2 gastrointes-
tinal and genitourinary adverse events, treatment arms 
could not be declared non-inferior. Cumulative G ≥3 
late genitourinary toxicity was also significantly higher 
after hf: 19·0% vs. 12·9% (p=0·021). no significant 
difference between treatment arms has been observed 
when it comes to cumulative G ≥3 late gastrointestinal 
toxicity: it was 3·3% for hf, 2·6% for Cf (p =0·55). 
There were no treatment-related deaths (20, 21, 22).
in the trial published by Arcangeli, 168 high-risk 
prostate cancer patients underwent conventional or 
hypofractionated radiotherapy (hf). Conventional 
fractionation was 80 Gy, with 2 Gy daily fractions, 5 
days a week. hypofractionated treatment consisted of 
62 Gy with 3.1 Gy per fraction; overall treatment time 
was 5 weeks. All patients received hormonal therapy 
for 9 months. After 70 months of follow up, isoeffec-
tiveness of the 2 fractionation schedules was con-
firmed. in a subset of patients whose initial PSA levels 
were ≤ 20 ng/ml, certain benefit in favor of hf could 
not be excluded (23).
Similarly, in trials published by hoffman and Pol-
lack comparing mh with Cf, no significant difference 
in five- year biochemical recurrence free (BRf) sur-
vival was observed (14, 24, 25, 26).
Randomized trials comparing conventional frac-
tionation with moderate hypofractionation in patients 
with prostate cancer are summarized in table 2 (14).
Extreme hypofractionation
in extreme hypofractionation (eh) radiotherapy is 
delivered with fractions higher than 3.4 Gy. They could 
be applied daily, weekly or on alternate days. total dose 
is up to 35- 50 Gy. delivery of a large radiation dose in 
small number of bigger fractions takes the advantage 
of the prostate’s α/β ratio estimated to be about 1.5 
Gy, which is considerably low. it is also referred to as 
stereotactic body radiation therapy (SBRt). modern 
image- guided techniques allow deliverance of brachy-
therapy-like doses with sparing of adjacent tissues. it 
has been evaluated in a number of phase i and ii trials 
on small groups of low-risk patients.
two trials with longer follow-up are those by Katz 
and meier (27, 28).
trial by Katz had a median follow up of 72 months. 
it recruited 324 low risk patients (PSA <10  ng/ml and 
Gleason score <7) and 153 intermediate-risk patients, 
with PSA levels between 10 and 20  ng/ml or Gleason 
score of 7. 51 patients received androgen deprivation 
therapy for up to 6 months. Cyber-knife system was 
used to deliver SBRt with fiducial based image guid-
ance. Applied doses were 35 Gy or 36.25 Gy, given 
daily in 5 fractions. After bowel preparation all pa-
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tine mixed in saline and instilled into the rectum. Pri-
mary outcome was biochemical disease-free survival as 
per Phoenix definition (bdfS). in 14 intermediate 
and 11 low-risk patients biochemical failures occurred. 
for patients in low risk group 7-year bdfS was 95.6% 
and for those in intermediate-risk 89.6% (p < 0.012). 
Within intermediate-risk group, patients with low in-
termediate-risk prostate cancer (n = 106), namely those 
with GS 6 and PSA >10 ng/ml or GS 3 + 4 and PSA 
<10 ng/ml had a significantly better bdfS compared 
to patients defined as high intermediate risk (n = 47, 
GS 3 + 4 and PSA between 10 and 20 ng/ml or GS 
4 + 3). bdfS figures were 93.5% for low intermediate 
and 79.3% for high intermediate risk group. There was 
no difference in biochemical disease-free survival 
among 36.25 Gy and 35 Gy radiation doses (27).
meier’s trial involved 309 patients in twenty-one 
center; 172 had a low-risk (ct1b-t2a, GS ≤6 and PSA 
≤10 ng/ml, lR) and the remaining 137 intermediate-
risk disease (ct1b-t2b with GS = 7 and PSA equal or 
below 10 ng/ml, or with GS ≤6 and PSA levels less or 
equal 20 ng/ml, iR). intermediate risk group patients 
were further subcategorized, according to memorial 
Sloan Kettering (mSK) risk classification system, as 
favorable or unfavorable. Prescribed dose was 40 Gy in 
5 fractions. Patients were treated with Cyber-knife 
system. during or after SBRt antiandrogen therapy 
was not permitted. Biochemical failure was defined as 
“nadir + 2”. failure was defined as biochemical recur-
rence or administration of any prostate cancer therapy: 
salvage, antiandrogen, or systemic.
for the entire patients’ group 5-year overall sur-
vival rate was 95.6% and 5-year disease free survival 
(dfS) rate 97.1%. The 5-year dfS rate was 97.3% for 
lR patients and 97.1% for iR patients. After a median 
follow-up of 61 months, 2 lR patients (1.2%) and 2 
iR patients (1.5%) experienced G 3 genitourinary ad-
verse events, occurring 11 to 51 months after treat-
ment. no grade 4 or 5 toxicities occurred (28).
King et al. performed a pooled analysis of prospec-
tive phase ii trials of SBRt from 8 institutions involv-
ing 1100 patients with clinically localized prostate can-
cer. 58% of patients had a low-risk disease, 30% inter-
mediate-risk and 11% of patients were classified as 
high risk. 14% of patients were given short course of 
androgen deprivation therapy (Adt). definition of 
PSA relapse was nadir PSA +2 ng/ml. median radia-
tion dose was 36.25 Gy in 4-5 fractions delivered using 
Cyber knife. 5-year biochemical relapse free survival 
(bRfS) rate after a median follow up of 36 months was 
93% for all patients. for low-risk patients 5-year bRfS 
rate was 95%, 84% for intermediate-risk patients and 
81% for high-risk patients (p < 0.001). 135 patients had 
a follow-up of minimally 5 years. Their 5-year bRfS 
rates were 99% if classified as low-risk group and 93% 
if classified as intermediate-risk group. Addition of 
Adt did not result in any difference (p = 0.71). in con-
clusion, these evidences support consideration of SBRt 
as a therapeutic option in patients with low and inter-
mediate-risk prostate cancer (29).
There are two phase iii clinical trials comparing 
extreme hypofractionation with conventional fraction-
ation: hyPo Rt PC and PACe B.
hyPo-Rt-PC randomizes intermediate risk pro-
state cancer patients to receive conventional radiother-
apy consisting of 78 Gy in 2 Gy daily fractions, 5 days/
week or 42.7 Gy in 7 fractions of 6.1 Gy given every 
other weekday, always including two weekends 
(hyPo- Rt arm). hypothesis of the trial is to dem-
onstrate 10 percentage points increase (70% to 80%) in 
freedom from failure for patients in tested arm of the 
trial (hyPo-Rt) 5 years upon the treatment. failure 
could be PSA rise or any clinical test showing activity 
of the disease (30).
PACe B trial includes cohort of patient with low 
risk prostate cancer (stage t1-t2, ≤ Gleason 3 + 4, 
PSA ≤ 20 ng/ml) within PACe trial. 874 patients in 
38 centers were randomized to SBRt (36.25 Gy given 
in 5 fractions during 1-2 weeks) or CfmhRt (con-
ventional fractionation, moderate hypofractionation 
radiotherapy; 78 Gy/39 fractions over 7.5 weeks, or 62 
Gy/20 fractions in 4 weeks). hormonal therapy was 
not allowed. Acute G ≥2 gastrointestinal (Gi) and 
genitourinary (GU) toxicity was not significantly dif-
ferent between the arms. frequency of acute G ≥2 Gi 
events was 12.1% in CmfhRt group vs. 10.1% in 
SBRt group, p=0.368. for acute G ≥2 GU events fig-
ures were for CfmhRt 27.2% vs. 23.2% for SBRt, 
p=0.179. late toxicity and efficacy data in terms of 
biochemical or clinical failure are pending (31).
According to nCCn (national Cancer Compre-
hensive network) guidelines, extreme hypofraction-
ation with daily doses up to 8 Gy is a treatment option 
for very low, low, favorable or good-prognostic inter-
mediate nCCn risk group of patients (32).
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Brachytherapy
Brachytherapy in prostate cancer can be used as a 
monotherapy in low and intermediate-risk patients or 
as a boost to external beam radiotherapy (eBRt) in 
intermediate and high-risk patients. depending on 
the characteristics of the radioactive source, it could be 
delivered as low dose rate (ldR) or high dose rate 
(hdR) radiotherapy. The advantage of radiotherapy is 
that it can be completed in one day. however, it re-
quires anesthesia, most often general, and can lead to 
acute urinary retention.
ldR brachytherapy uses permanent seeds. The 
most common sources are iodine-125, Palladium-103 
and Cesium-131 isotopes. Radiation dose is delivered 
over weeks and months requiring radiation protection 
for both patients and carers. According to eStRo/
eAU/eoRtC recommendations, patients eligible for 
ldR would be those with stage ct1b-t2a n0, m0; 
iSUP grade 1 with ≤ 50% of biopsy cores involved 
with cancer or iSUP grade 2 with ≤ 33% of biopsy 
cores involved with cancer; an initial PSA level of ≤ 10 
ng/ml; a prostate volume of < 50 cm3; an internation-
al Prostatic Symptom Score (iPSS) ≤ 12 and maximal 
flow rate > 15 ml/min on urinary flow test. Absolute 
contraindications are limited life expectancy, unac-
ceptable operative risks, metastatic disease, ataxia tel-
angiectasia, previous large transurethral resection that 
precludes seed placement and accurate dosimetry and 
absence of rectum. (13, 33).
Results of ldR brachytherapy trials are shown in 
table 3. (34, 35, 36, 37, 38, 39, 40).
hdR brachytherapy uses radioactive sources that 
are being placed into the prostate temporarily. iridi-
um-192 (iR-192) isotope is being introduced through 
implanted needles or catheters. Radiation dose is de-
livered in minutes, implantation is temporary and 
there are no radiation protection issues for patient or 
carers. Radiation can be delivered in single or multiple 
fractions. fractionated hdR brachytherapy as mono-
therapy can be offered to patients with low- and inter-
mediate-risk prostate cancer. in patients with interme-
diate and high-risk prostate cancer it can be used as a 
boost to external beam radiotherapy. Patients with 
significant urinary outflow symptoms are not candi-
dates for hdR boost (13,41).
A randomized phase-iii trial compared external 
beam radiotherapy (eBRt) alone with eBRt com-
bined with high-dose-rate brachytherapy boost 
(hdR-Btb) in 218 patients with localized prostate 
adenocarcinoma. Patients in eBRt arm received a to-
tal dose of 55 Gy in 20 daily fractions while patients in 
hdR-Btb arm received eBRt 35.75 Gy in 13 frac-
tions followed by hdR-Bt boost of 2x 8.5 Gy in 24 
h. Biochemical/clinical relapse-free survival (RfS) was 
the primary endpoint. Secondary endpoints were over-
all survival (oS), urinary and bowel toxicity. After 4 
years median time to relapse was 116 months in eBRt 
+ hdR-Btb group, compared to 74 months in eBRt 
only group. (p = 0.04). in multivariate analysis treat-
ment arm, risk category and Adt were significant co-
variates for risk of relapse. differences in oS were not 
significant. incidence of severe late urinary and bowel 
morbidity was similar: the 5 and 7-year incidence for 
patients with any severe urinary symptom was 26% 
and 31% for those treated with eBRt + hdR-Btb 
compared with 26% and 30% for patients in eBRt 
Table 3. Reported outcomes for prostate cancer patients treated with LDR brachytherapy
Study number of patients
Risk group (%) follow up 
(years)
Biochemical control (%)





Blasko et al (34) 230 45 46 9 9 87 79 68 100
Zelefsky et al (35) 2693 55 40 5 8 82 70 40
henry et al (36) 1298 44 33 14 10 86 77 61
morris et al (37) 1006 58 42 0 10 99 83.5
funk et al (38) 966 71 29 0 10 90 74 98 74
Kittel et al (39) 1989 61 30 5 10 87 79 68 97 76
fellin et al (40) 2237 66 26 2 7 93 78 73 98 89
CSS: cause specific survival; oS: overall survival
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only arm (p = 0.5). The incidence of severe bowel 
events was 7% and 6%, respectively, at 5 and 7 years (p 
= 0.8) (42).
Radiotherapy in disease relapse  
- salvage radiotherapy
in case of locoregional relapse of the disease, with 
radiotherapy is possible to achieve cure or at least 
long-term control, even in previously irradiated pa-
tients.
in patients who experience biochemical relapse af-
ter radical prostatectomy, who were not irradiated and 
in whom diagnostic procedures exclude metastatic dis-
ease, salvage radiotherapy is indicated. it refers to ir-
radiation of prostate and seminal vesicles bed with 
doses up to 72 Gy with the addition of hormonal ther-
apy. The role of whole pelvic irradiation is still undeter-
mined. While it is still unclear whether radiotherapy 
should be given in adjuvant setting in patients with 
higher risk of locoregional relapse, or as a salvage treat-
ment upon biochemical recurrence, it is undoubtedly 
proved that early salvage therapy is better than late. 
Therefore, irradiation should begin when PSA levels 
reach values between 0.2 and 0.5 ng/ml, or even earlier, 
with PSA level below 0.2 (43, 44).
Studies of salvage radiotherapy are summarized in 
table 4 (13, 44, 45, 46, 47).
Regarding recommended dose, King et al have 
compared 60 Gy and 70 Gy in 38 and 84 patients with 
pathologically negative lymph nodes, respectively. Ra-
diotherapy was given beyond 6 months after radical 
prostatectomy and when PSA was detectable. Whole 
pelvic Rt up to 50 Gy was delivered to 59% of pa-
tients. 56% of patients also received 4-months total 
androgen suppression with lhRh agonist and oral 
antiandrogen. Biochemical relapse was defined as de-
tectable PSA level confirmed on repeat testing and ris-
ing on subsequent testing. After a median follow-up of 
>5 years 60 patients experienced biochemical relapse. 
median time to relapse was 1.2 years. for patients re-
ceiving Rt alone the 5-year biochemical relapse free 
survival (bRfS) rate was 17% vs. 55% (p = 0.016), and 
for those receiving prostate-bed-only Rt it was 23% 
vs. 66% (p = 0.037) for doses of 60 Gy vs. 70 Gy, re-
spectively. Approximately 2.5% improvement in 5-year 
bRfS was achieved for each additional Gy. Therefore, 
a clinically significant dose response from 60 Gy to 70 
Gy was observed in the setting of salvage Rt after 
prostatectomy (48).
Disease relapse in pelvic lymph nodes
Patients with lymph node metastasis only have a 
better prognosis than those with metastasis on other 
sites with median overall survival and cancer-specific 
survival of 43 and 61 month, respectively (49).
Table 4. Studies of post-prostatectomy salvage radiotherapy (13)







Rt dose Adt bned/PfS (year) 5-year results
Bartkowiak,  
et al. 2017 (44)
464 71 0.31 66.6 Gy no 54% (5.9) 73% vs. 56%; PSA
< 0.2 vs. ≥ 0.2 ng/ml  
p < 0.0001
Soto, et al,  
2012 (45)
441 36 < 1 (58%) 68 Gy 24% 63/55% (3)
Adt/no Adt
44/40% Adt/no Adt  
p < 0.16
Stish, et al.  
2016 (46)
1,106 107 0.6 68 Gy 16% 50% (5)
36% (10)
44% vs. 58%; PSA
≤ 0.5 vs. > 0.5 ng/ml  
p < 0.001
tendulkar,  
et al. 2016 (47)
2,460 60 0.5 66 Gy 16% 56% (5) SRt; PSA < 0.2 ng/ml
71% 0.21-0.5 ng/ml 63% 
0.51-1.0 ng/ml 54% 
1.01-2.0 ng/ml 43%  
> 2 ng/ml 37% p < 0.001
Adt = androgen deprivation therapy; oS = overall survival; SRt = salvage radiotherapy, bned = biochemically no evidence of disease, 
PfS =progression free survival
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Subgroup of patients with pelvic lymph nodes me-
tastasis only after radical prostatectomy, regardless of 
previous prostate bed adjuvant radiotherapy, should be 
referred to as potentially curable. They should be offered 
local treatment, with or without hormonal therapy.
in multicenter trial published by ost et al., 72 pros-
tate cancer patients with ≤3 lymph nodes at the time 
of recurrence were treated with SBRt, which was de-
fined as a radiotherapy dose of at least 5 Gy per frac-
tion to a biological effective dose of at least 80 Gy to 
all metastatic sites. The median distant progression-
free survival was 21 months and most relapses (68%) 
occurred in nodal regions. Relapses after pelvic nodal 
SBRt were located in the pelvis. 5-year distant pro-
gression free survival was 13% (50).
tran et al. reviewed data of 53 oligorecurrent pros-
tate cancer patients treated with elective nodal radio-
therapy (enRt). 38 patients had a single nodal me-
tastasis located in the pelvis. All patients underwent 
enRt between 45 and 50.4 Gy with a boost on posi-
tive nodes up to 69 Gy. Concomitant androgen depri-
vation therapy was administered to all patients for a 
median time of 6 months. After a median follow-up of 
44 months, the 5-year biochemical disease-free and 
distant progression-free survival (dPfS) rates were 
43% and 58%, respectively (51).
in the trial published by lepinoy, comparison be-
tween salvage extended field radiotherapy (s-efRt) 
and salvage involved field radiotherapy (s-ifRt) in 
patients with 18f-fluorocholine (fCh) Pet/Ct+ 
nodal oligorecurrences from prostate cancer in terms 
of times to failure (ttf) and toxicity was made. of 62 
patients with positive lymph nodes only who under-
went fCh Pet/Ct for a rising PSA level after radi-
cal prostatectomy or radiotherapy, 35 had s-ifRt and 
27 had s-efRt. 3-year failure rates were 55.3% in the 
s-ifRt group and 88.3% in the s-efRt group 
(p = 0.0094). There was a strong trend toward better 
outcomes with s-efRt even after adjusting for con-
comitant androgen-deprivation therapy. After a me-
dian follow-up of 41.8 months (range 5.9-108.1 
months), no differences were observed in acute or late 
gastrointestinal and genitourinary toxicities of grade 2 
or more between the two groups (52).
These data suggest that in subgroup of patients 
with pelvic nodal relapse only, extended field radio-
therapy should be treatment of choice rather than ste-
reotactic irradiation of affected lymph nodes.
Discussion
There is a robust data available proving efficacy of 
radiotherapy in prostate cancer in different stages of 
the disease. introduction of iSUP grade system, fur-
ther stratification of risk groups and different study 
endpoints, as well as their definition, makes the inter-
pretation and comparison of those trials truly chal-
lenging.
dose escalation led to better biochemical control 
of the disease, which has in some trials translated into 
better survival, especially in patients in higher risk 
groups. The impact of dose escalation on acute and late 
treatment toxicities is quite inconsistent across the 
published trials but, in general, late gastrointestinal 
toxicity is more frequently observed in patients receiv-
ing higher radiation doses. According to nCCn 
guidelines, doses between 72 and 81 Gy, standard frac-
tionation, are acceptable across the risk groups (32).
moderate hypofractionation (mf) with daily doses 
up to 3.4 Gy is convenient due to shorter overall treat-
ment time but could also lead to better disease control 
regarding low α/β ratio of prostate cancer. it has prov-
en its non-inferiority in a number of trials in terms of 
biochemical control of the disease. Again, no consis-
tent conclusions regarding toxicity could be made: no 
difference between the two arms was reported in 
ChhiP and PRofit trial, while in RtoG trial late 
toxicity was more common with mf (17, 18, 19). As 
far as superiority trials are concerned, four of those 
failed to demonstrate any difference in efficacy, includ-
ing metastasis-free, cancer-specific survival and overall 
survival between moderate hypofractionation and 
conventional fractionation. According to AStRo 
(American Society for Radiation oncology), ASCo 
(American Society of Clinical oncology) and AUA 
(American Urological Association) guidelines, in men 
with low, intermediate and high risk prostate cancer, 
moderate hypofractionation should be offered with 
regimens of 60 Gy in 20 fractions and 70 Gy in 28 
fractions, since they are supported with the largest evi-
dentiary base. one optimal regimen cannot be deter-
mined since most of the multiple fractionation schemes 
evaluated in clinical trials have not been compared 
head to head. Though mh has a similar risk of acute 
and late genitourinary and late gastrointestinal toxicity 
compared to conventionally fractionated radiotherapy, 
one should bear in mind limited follow-up beyond five 
years for most trials (53).
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extreme hypofractionation (eh), also referred as 
stereotactic body radiation therapy (SBRt), has been 
evaluated in a number of small phase i and ii trials and 
the results of two-phase iii trials comparing it with 
conventional fractionations are awaiting. According to 
AStRo, ASCo and AUA guidelines, it can be of-
fered in men with low-risk prostate cancer who de-
cline active surveillance as an alternative to conven-
tional fractionation. in men with intermediate-risk 
prostate cancer it may also be offered as an alternative 
to conventional fractionation, but the task force 
strongly encourages that these patients be treated as 
part of a clinical trial or multi-institutional registry. in 
men with high-risk prostate cancer eh should not be 
used outside of a clinical trial. Acceptable doses are 35 
to 36.25 Gy in 5 fractions of 7 to 7.25 Gy (53).
Brachytherapy presents a valuable treatment op-
tion proven in a number of clinical trials, either as a 
sole modality in low and intermediate risk prostate 
cancer patients or combined with external beam radio-
therapy in both intermediate and high-risk patients. 
nevertheless, after summarizing evidence form recent 
randomized trials, American Brachytherapy Society 
task Group finds out that combination of brachyther-
apy and external beam therapy may become the stan-
dard of care for patients with high-risk prostate cancer 
(54). Unfortunately, its availability can be limited. 
When opting for brachytherapy in order to keep its 
toxicity to a minimum, patient selection seems to be 
crucial (33).
in case of disease relapse, if it is locoregional, radio-
therapy can still be a curative method. When it comes 
to biochemical relapse in previously unirradiated pa-
tients, radiotherapy of the prostate and seminal vesi-
cles bed should be delivered early, before PSA reaches 
the level of 0.5 ng/ml. Patients with metastases in pel-
vic lymph nodes only should be treated with curative 
intent with a whole pelvis irradiation instead of an in-
volved field.
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Sažetak
RAdioteRAPiJA RAKA PRoStAte:  
PRimARnA RAdioteRAPiJA i RAdioteRAPiJA U PoVRAtU BoleSti
K. Antunac
Radioterapija predstavlja jedan od osnovnih modaliteta liječenja bolesnika s rakom prostate u gotovo svim stadijima 
bolesti. može se koristiti kao vanjsko zračenje, kao brahiterapija (unutarnje zračenje) ili kombinacija ove dvije metode. Više 
doze zračenja su dokazano učinkovitije od nižih a umjereno hipofrakcionirano zračenje dozama do 3,4 Gy po frakciji je 
jednako učinkovito kao i zračenje standardnim frakcioniranjem od 1,8- 2 Gy po frakciji. Stereotaksijsko zračenje dozama od 
3,4 do 7,25 Gy po frakciji predstavlja vrijednu opciju kod određenih podskupina bolesnika. U slučaju lokoregionalnog po-
vrata bolesti, zračenje se može provoditi s ciljem izlječenja bolesnika.
Ključne riječi: rak prostate, radioterapija, brahiterapija, hipofrakcioniranje, stereotaksijsko zračenje, spasonosna radioterapija
